KeyCorp vs uniQure N.V. Ordinary Shares — how do they compare? KeyCorp trades at $19.83 (market cap $21.25B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: KeyCorp is far larger — about 14.4× uniQure N.V. Ordinary Shares's market cap, and KeyCorp pays a 4.12% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| KEY | QURE | |
|---|---|---|
Market Cap | $21.25B | $1.48B |
Volume | 17,676,934 | 2,488,780 |
Sector | Financials | Health |
52-Week High | $23.99 | $70.59 |
52-Week Low | $16.78 | $9.03 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $34.43B | $728.62M |
Dividend Yield | 4.12% | — |
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.79, down 1.49% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.64 and net income margin of 26.72%. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.21 dividend. Analyst consensus is bullish with a $25.00 price target, though recent news highlights competitive dividend pressures.
The outlook for KEY is positive based on earnings momentum and valuation, but risks include interest rate sensitivity and frozen dividends. Upside potential exists if loan growth and fee income continue to drive revenue, yet investor sentiment is cautious amid technical weakness and macroeconomic uncertainty.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →